Many projects quickly move from discovery to sequencing, recombinant redevelopment, humanization, optimization, and expression. Managing these steps across multiple vendors can slow progress and add complexity.
 
At Synbio Technologies, we provide an integrated workflow to support antibody projects from lead discovery to recombinant antibody production.
 
Key solutions include:
• 
Antibody Discovery – Hybridoma, single B-cell, and AI-powered platforms across
  multiple species
• 
NEW Rabbit Monoclonal Antibodies – High affinity and broader epitope coverage for
  difficult targets
• 
Nanobody Services – Small, stable binders with versatile research and therapeutic
  potential
• 
Hybridoma Sequencing – Near-100% success, U.S.-based processing, and
  unbeatable price for VH/VL sequence recovery
• 
Humanization, Engineering & Recombinant Expression – Optimize antibody
  performance and support downstream development
 
Backed by AI-powered gene synthesis and molecular biology expertise, we help streamline the path from antibody discovery to validated recombinant candidates.
 
 
 
Synbio Technologies LinkedIn X Facebook Facebook

Thank you for connecting with us! Click "Subscribe" to receive valuable insights and news. If you prefer not to receive further emails, just hit "Unsubscribe" — your choice is always respected.
Synbio Technologies LLC
9 Deer Prk Dr., Suite J-25, Monmouth Junction, NJ 08852, USA